| REVIEW ARTICLE |
|
| Year : 2018 | Volume
: 13
| Issue : 1 | Page : 51-55 |
|
|
Paradigm shift in clinical trial regulations in India
Sandeep Lahiry1, Rajasree Sinha2, Shouvik Choudhury1, Ayan Mukherjee1, Suparna Chatterjee1
1 Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
2 Department of Pediatrics, Medical College and Hospital, Kolkata, West Bengal, India
Correspondence Address:
Prof. Suparna Chatterjee
Department of Pharmacology, Institute of Postgraduate Medical Education and Research, 244 A. J. C. Bose Road, Kolkata - 700 020, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/injr.injr_110_17
|
|
|
India has the potential to contribute meaningfully to global clinical drug development. A critical enabler to achieve this potential is a balanced, predictable, and scientifically robust regulation involving clinical studies. In the past few years, the country's regulatory milieu has witnessed a positive transformation to favour ethical conduct of clinical trials, while appropriately supporting patient safety. Numerous amendments to existing policies governing the conduct of clinical studies are predicted to bring a paradigm shift in the overall regulatory scenario. In such view, it is important for us as academicians, to be abreast of such changes. We, therefore, discuss major regulatory highlights involving clinical research in India.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
